CompletedNCT01875822
Official study titleOpen Label Study of Curcumin C-3 Complex, the Prototypal Epigenetic Modulator, as an Augmentation Strategy to Antipsychotic Therapy,for Improving Negative Symptoms and Cognition in Schizophrenia
This study has finished and is no longer accepting participants.
In San JuanSchizophrenia, DepressionInterventional studyAges 18–65
- Countries
- United States
- Sponsor
- Woodbury, Michel, M.D.
CompletedNCT01248195
This study has finished and is no longer accepting participants.
Multiple locations, including MelbourneSchizophreniaMedication studyAges 18–40
- Countries
- Australia, France, United Kingdom, + 13 others
- Sponsor
- Rene Kahn
CompletedNCT01555814
Official study titleOptimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): the Effects of D2 Antagonism on Candidate Endophenotypes
This study has finished and is no longer accepting participants.
In Glostrup MunicipalitySchizophreniaMedication studyAges 18–40
- Countries
- Denmark
- Sponsor
- Birte Glenthoj
CompletedNCT01752712
Official study titleCombined Oxytocin and CBSST for Social Function in People With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including San DiegoSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
CompletedNCT01028677
Official study titleOxytocin Treatment of Social Deficits and Paranoia in Schizophrenia
This study has finished and is no longer accepting participants.
In Chapel HillSchizophreniaMedication studyAges 18–55
- Countries
- United States
- Sponsor
- University of North Carolina, Chapel Hill
CompletedNCT01394471
This study has finished and is no longer accepting participants.
In Chapel HillSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- University of North Carolina, Chapel Hill
CompletedNCT03873337
Official study titlePersistence Targeted Smoking Cessation in Schizophrenia (PTSC-S)
This study has finished and is no longer accepting participants.
In New BrunswickSchizophrenia, AddictionMedication studyAges 18–70
- Countries
- United States
- Sponsor
- Rutgers, The State University of New Jersey
WithdrawnNCT05974527
Official study titlePilot Study 1: Efficacy and Safety of Sublingual Dexmedetomidine (BXCL501) for the Treatment of Agitation in the Emergency Department
This study was withdrawn before enrollment.
Location not clearly listedSchizophrenia, BipolarityMedication studyAges 18+
- Countries
- Sponsor
- Brigham and Women's Hospital
CompletedNCT00793780
Official study titlePilot Trial of Naltrexone for Obesity in Women With Schizophrenia
This study has finished and is no longer accepting participants.
In New HavenSchizophreniaMedication studyAges 18–70
- Countries
- United States
- Sponsor
- Yale University
CompletedNCT00918021
Official study titleOlanzapine Augmentation in Clozapine-resistant Schizophrenia: a Randomized Double-blind Study
This study has finished and is no longer accepting participants.
In KuopioSchizophreniaMedication studyAges 18+
- Countries
- Finland
- Sponsor
- Niuvanniemi Hospital
CompletedNCT00728728
This study has finished and is no longer accepting participants.
In DurhamSchizophreniaMedication studyAges 21–65
- Countries
- United States
- Sponsor
- VA Office of Research and Development (Government agency)
CompletedNCT00330863
Official study titlePreventing Relapse: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE)
This study has finished and is no longer accepting participants.
Multiple locations, including Los AngelesSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Northwell Health